4801-58-5

Usage

Uses

1. Used in Pharmaceutical Industry:
1-HYDROXYPIPERIDINE is used as a base for Fmoc-based solid phase peptide synthesis for its ability to facilitate the formation of peptide bonds in a controlled and efficient manner, which is crucial in the development of new drugs and therapies.
2. Used in Chemical Industry:
1-HYDROXYPIPERIDINE is used as a light stabilizing agent for its capacity to protect materials from the degrading effects of light exposure, thus enhancing the durability and longevity of products in various applications.
3. Used in Research and Development:
1-HYDROXYPIPERIDINE serves as an important intermediate in the synthesis of various pharmaceuticals, agrochemicals, and other specialty chemicals due to its unique chemical properties and reactivity.

Synthesis Reference(s)

The Journal of Organic Chemistry, 53, p. 5856, 1988 DOI: 10.1021/jo00260a012

InChI:InChI=1/C5H11NO/c7-6-4-2-1-3-5-6/h7H,1-5H2

Upstream product

• 110-89-4 piperidine 
• 4801-57-4 N-ethylpiperidine N-oxide 
• 93-59-4 Perbenzoic acid 
• 19653-33-9 ethyl piperidine-1-propionate 
• 766-09-6 1-ethyl-piperidine 
• 5542-49-4 piperidin-1-yl benzoate 
• 6635-57-0 1,5-pentanedioxime 
• 95650-50-3 5-(1-Oxy-piperidin-1-yl)-pentan-1-ol 
• 111-24-0 1,5-dibromo-pentane 
• 3088-41-3 3-(piperidin-1-yl)propionitrile 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 109-99-9 tetrahydrofuran 
• 4629-80-5 1,3-dimethyl-4-piperidinone 
• 109-72-8 n-butyllithium 

Downstream Products

• 4816-77-7 1-benzyloxycarbonyloxy-piperidine 
• 5868-64-4 N-Morpholinomethoxy-piperidin 
• 3515-13-7 diphenyl-(1-piperidin-1-yloxy-butoxy)-borane 
• 70546-85-9 2-phenyl-3,3a,4,5,6,7-hexahydro-2H-isoxazolo<2,3-a>pyridine 
• 70546-85-9 (2S,3aS)-2-Phenyl-hexahydro-isoxazolo[2,3-a]pyridine 
• 134721-10-1 trans-8-<2-(p-Benzyloxyphenyl)ethyl>-9-oxa-1-azabicyclo<4.3.0>nonane 
• 139883-70-8 (3R*,3aS*,9aS*,9bR*)-Octahydro-3-(2-benzyloxy)ethyl-1H-furo<3',4':4,5>isoxazolo<2,3-a>pyridin-1-one 
• 139883-70-8 (3S*,3aS*,9aS*,9bR*)-Octahydro-3-(2-benzyloxy)ethyl-1H-furo<3',4':4,5>isoxazolo<2,3-a>pyridin-1-one 
• 139883-70-8 (3S*,3aR*,9aS*,9bS*)-Octahydro-3-(2-benzyloxy)ethyl-1H-furo<3',4':4,5>isoxazolo<2,3-a>pyridin-1-one 
• 110-89-4 piperidine 
• 109253-33-0 1-benzhydryloxy-piperidine 
• 171019-33-3 (1S,2S)-1-(S)-Piperidin-2-yl-1-((R)-toluene-4-sulfinyl)-propan-2-ol 
• 171019-30-0 (2S,3S,3aS)-2-Phenyl-3-((R)-toluene-4-sulfinyl)-hexahydro-isoxazolo[2,3-a]pyridine 
• 171019-34-4 (S)-2-[(1S,2S)-2-Hydroxy-1-((R)-toluene-4-sulfinyl)-propyl]-piperidine-1-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Selective Oxidation of Secondary Amines to N,N-Disubstituted Hydroxylamines by Choline Peroxydisulfate

N,N-Disubstituted hydroxylamines were prepared directly from secondary amines by a reliable method using an oxidizing task-specific ionic liquid, choline peroxydisulfate. The operational simplicity, high selectivity, and green reaction conditions, make this method efficient and practical.

PIPERIDINE DERIVATIVE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE

To provide a compound having an effect for preventing photolysis of a liquid crystal composition, and having a high solubility in the liquid crystal composition, a liquid crystal composition containing the compound, and a liquid crystal display device including the composition. The compound is represented by formula (1), a liquid crystal composition contains the compound, and a liquid crystal display device includes the composition: [in-line-formulae]M(Z-Q)a(Rb)b??(1)[/in-line-formulae] wherein, in formula (1), a is 1 to 4, and b is a numerical value: (4?a); M is an organic group; Z is a single bond or the like; and Q is a monovalent group represented by formula (Q-1), (Q-2) or (Q-3), in which Ra and Rb are hydrogen, alkyl or the like.

Synthesis of N,N,O-Trisubstituted Hydroxylamines by Stepwise Reduction and Substitution of O-Acyl N,N-Disubstituted Hydroxylamines

Diverse N,N,O-trisubstituted hydroxylamines, an under-represented group in compound collections, are readily prepared by partial reduction of N-acyloxy secondary amines with diisobutylaluminum hydride followed by acetylation and reduction of the so-formed O-acyl-N,N-disubstituted hydroxylamines with triethylsilane and boron trifluoride etherate. Use of carbon nucleophiles in the last step, including allyltributylstannane, silyl enol ethers, and 2-methylfuran, gives N,N,O-trisubstituted hydroxylamines with branching α- to the O-substituent. N,N-Disubstiuted hydroxylamines are conveniently prepared by reaction of secondary amines with dibenzoyl peroxide followed by diisobutylaluminum hydride reduction.

Novel gamma secretase inhibitors

This invention discloses novel gamma secretase inhibitors of the formula: wherein: R1 is a substituted aryl or substituted heteroaryl group; R2 is an R1 group, alkyl, —XC(O)Y, alkylene-XC(O)Y, cycloalkylene-X—C(O)—Y, —CH—X—C(O)—NR3—Y or —CH—X—C(O)—Y, wherein X and Y are as defined herein; each R3 and each R3A are independently H, or alkyl; R11 is aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, arylcycloalkyl, heteroarylalkyl, heteroarylcycloalkyl, arylheterocycloalkyl, or alkoxyalkyl. Also disclosed is a method of treating Alzheimer's Disease using one or more compounds of the invention.

Cyanine dyes

The invention provides a novel class of cyanine dyes that are functionalized with a linker moiety that facilitates their conjugation to other species. Also provided are conjugates of the dyes, methods of using the dyes and their conjugates and kits including the dyes and their conjugates.

Novel gamma secretase inhibitors

This invention discloses novel gamma secretase inhibitors of the formula: wherein: R1 is a substituted aryl or substituted heteroaryl group; R2 is an R1 group, alkyl, —XC(O)Y, alkylene-XC(O)Y, cycloalkylene-X-C(O)—Y, —CH—X—C(O)—NR3—Y or —CH—X—C(O)—Y, wherein X and Y are as defined herein; each R3 and each R3A are independently H, or alkyl; R11 is aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, arylcycloalkyl, heteroarylalkyl, heteroarylcycloalkyl, arylheterocycloalkyl, or alkoxyalkyl. Also disclosed is a method of treating Alzheimer's Disease using one or more compounds of the invention.

A convenient synthesis of secondary hydroxylamines

The oxidation of a range of β-cyanoethyl tertiary amines with mCPBA gives the corresponding N-oxides, which can be isolated or undergo Cope-elimination to give secondary hydroxylamines in excellent yield.

Oxidation-Cope elimination: A REM-resin cleavage protocol for the solid-phase synthesis of hydroxylamines

We have established that using an oxidation-Cope elimination cleavage protocol allows for the synthesis of N,N-disubstituted hydroxylamines from REM resin (polymer-bound benzyl acrylate). Michael addition of a secondary amine or addition of a primary amine followed by reductive alkylation provides polymer-bound tertiary amines. Oxidation of these resin-bound tertiary amines with MCPBA is followed by concomitant Cope elimination to regenerate the polymer-bound acrylate and provide the cleaved hydroxylamines.

NEW SYNTHESIS OF (METHOXYCARBONYL)-INDOLIZIDIN-7-ONE AND -QUINOLIZIDIN-2-ONE: AN ACCESS TO β-AMINO ACIDS WITH INDOLIZIDINE AND QUINOLIZIDINE BACKBONE

Two protected β-amino acids containing the indolizidine or quinolizidine skeleton have been synthesised.The key step of the strategy is represented by the new synthesis of indolizidinone and quinolizidone II carried out by the opening of the tricyclic 1,3-dipolar cycloaddition products 17 or 18 with DABCO.A new and more convenient method for the synthesis of the cyclic hydroxylamines 13 and 14 precursors of nitrones is also reported.